本帖最后由 老马 于 2013-3-13 13:43 编辑
. q, d) k Y- y) b5 @" v& x3 D# S. n3 t+ u
健择（吉西他滨）+顺铂+阿瓦斯汀9 o! m8 S2 W4 x5 k u- _0 U" z
Gemzar +Cisplatin + Avastin- h8 [) g6 o5 ?9 e9 { C
http://annonc.oxfordjournals.org/content/21/9/1804.full
4 q% q4 y8 }% F& _& mOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) . o& V5 t; q) ~! O+ R& n3 c
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 m) z- l* U; R; Q' d* S6 r( fResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 r1 R; |" e6 l. g
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 825)
" l0 \/ }) G. O* u) q N
华为网盘附件：
, H s% B% }) \【华为网盘】ava.JPG$ \7 S5 E, {6 v" m3 k" Y
|
显身卡
